STOCK TITAN

Boston Scientific Corporation - $BSX STOCK NEWS

Welcome to our dedicated page for Boston Scientific Corporation news (Ticker: $BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scientific Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Boston Scientific Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Boston Scientific Corporation's position in the market.

Rhea-AI Summary

Boston Scientific announced positive six-month results from the MODULAR ATP study of the mCRM System, which integrates the EMBLEM S-ICD and EMPOWER LP. The study met all safety and efficacy endpoints, showing a 97.5% major complication-free rate and a 98.8% communication success rate between devices. The ATP success rate was 61.3%, with no patients requesting therapy deactivation. The EMPOWER LP demonstrated stable device fixation. Findings were presented at Heart Rhythm 2024 and published in The New England Journal of Medicine. The APPRAISE ATP trial also supported the modular therapy approach, showing a small reduction in first all-cause shocks over five years in a large patient group. FDA approval is anticipated in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Boston Scientific (NYSE: BSX) has elected Dr. Cheryl Pegus to its board of directors, bringing over 25 years of clinical and business leadership experience to the company. Dr. Pegus has held various prominent positions in the healthcare industry, demonstrating a strong commitment to improving healthcare quality and accessibility. Her appointment is expected to enhance Boston Scientific's strategic growth and patient care initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
management
-
Rhea-AI Summary

Boston Scientific (NYSE: BSX) is set to participate in two upcoming investor conferences in May. The executives will engage in question-and-answer sessions at Bank of America's 2024 Health Care Conference on May 14 and at Bernstein's 40th Annual Strategic Decisions Conference on May 29. The webcasts and replays of both events will be accessible on the company's investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
conferences
Rhea-AI Summary
Boston Scientific (NYSE: BSX) reported strong financial results for the first quarter of 2024, with net sales of $3.856 billion, a 13.8% increase on a reported basis. The company achieved GAAP net income of $495 million, compared to $300 million a year ago, and an adjusted EPS of $0.56. Various business segments and regions showed growth, with significant developments in product launches, clinical trials, and regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
-
Rhea-AI Summary
Boston Scientific initiates NAVIGATE-PF study for FARAVIEW Software Module and FARAWAVE Nav Pulsed Field Ablation Catheter in atrial fibrillation treatment, aiming to improve patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
none
-
Rhea-AI Summary
Boston Scientific (BSX) will host a conference call on April 24, 2024, discussing financial results for the first quarter of 2024. The call, led by Mike Mahoney and Dan Brennan, will be followed by a news release. Investors can access the webcast on the company's investor website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
Rhea-AI Summary
Scivita Medical Technology Co., and Boston Scientific sign an expanded strategic cooperation agreement to introduce iterative endoscopic technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
none
-
Rhea-AI Summary
Axonics, Inc. (AXNX) stockholders vote to adopt merger agreement with Boston Scientific (BSX). The majority of shares voted in favor of the merger. The closing is expected in the first half of 2024, subject to certain conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
-
Rhea-AI Summary
Boston Scientific Corporation receives FDA approval for AGENT Drug-Coated Balloon to treat coronary in-stent restenosis, providing a safe and effective alternative with positive clinical trial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
Rhea-AI Summary
Boston Scientific Corporation (BSX) completes a public offering of €2 billion in notes to finance the acquisition of Axonics, Inc., among other expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
Boston Scientific Corporation

NYSE:BSX

BSX Rankings

BSX Stock Data

110.51B
1.46B
0.19%
93.66%
0.85%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
MARLBOROUGH

About BSX

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.